CYTK CYTOKINETICS INC

CIK 0001061983 50 ready 8-Ks latest May 8, 2026, 7:59 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing May 27, 2026, 4:00 PM ET

Top materiality 0.90

Event mix other_material ×23 · earnings ×11 · leadership ×8

Sentiment 17 pos · 0 neg · 33 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for CYTK

Highest-materiality recent filing

Cytokinetics announces European Commission approval of MYQORZO (aficamten) for obstructive HCM

February 17, 2026, 6:59 PM ET regulatory materiality 0.90 positive item 8.01

European Commission approved MYQORZO (aficamten) for symptomatic obstructive HCM in adults.
Approved dosage strengths: 5 mg, 10 mg, 15 mg, and 20 mg tablets.

Read filing →

May 8, 2026, 7:59 PM ET other material materiality 0.80 neutral item 8.01 item 9.01

Cytokinetics prices $760M public offering of 11.34M shares at $71/sh

Offering of 9,859,155 shares at $71.00 per share; underwriters' option for 1,478,873 shares exercised in full.
May 5, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Cytokinetics reports Q1 2026: MYQORZO net product rev $4.8M, net loss $206M; ACACIA-HCM meets endpoints

MYQORZO net product revenue $4.8M for ~9 weeks; total revenue $19.4M (incl $11.9M milestone from Bayer).
February 24, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Cytokinetics Q4 net loss $183M; MYQORZO launch underway; cash $1.22B; guides 2026 spend $830-870M

Net loss Q4 2025 $183M ($1.50/sh) vs $150M ($1.26) Q4 2024; full year loss $785M ($6.54) vs $589.5M ($5.26).
February 17, 2026, 6:59 PM ET regulatory materiality 0.90 positive item 8.01

Cytokinetics announces European Commission approval of MYQORZO (aficamten) for obstructive HCM

European Commission approved MYQORZO (aficamten) for symptomatic obstructive HCM in adults.
December 19, 2025, 6:59 PM ET regulatory materiality 0.90 positive item 8.01

Cytokinetics receives FDA approval for MYQORZO (aficamten) to treat symptomatic oHCM

FDA approved MYQORZO (aficamten) on Dec 19, 2025 for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
December 12, 2025, 6:59 PM ET regulatory materiality 0.80 positive item 8.01

CHMP recommends EU approval of Cytokinetics' MYQORZO for obstructive HCM

CHMP adopted positive opinion recommending EU marketing authorization for MYQORZO (aficamten).
November 5, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Cytokinetics Q3 net loss $306M; aficamten PDUFA on track; raises $750M convertible notes

Q3 net loss $306.2M ($2.55/share) vs $160.5M loss in prior year; includes $121.2M debt conversion expense.
September 22, 2025, 7:59 PM ET debt materiality 0.75 neutral item 1.01 item 2.03 item 3.02 item 8.01 item 9.01 ◈ Equity Issuances ×3◈ Debt Financings

Cytokinetics issues $750M 1.75% convertible notes; refinances $399.5M of 2027 notes

Issued $750M aggregate principal of 1.75% convertible senior notes due 2031; net proceeds ~$729.4M.
September 16, 2025, 7:59 PM ET other material materiality 0.70 neutral item 8.01

Cytokinetics provides FDA/EMA update on aficamten; plans to draw $100M Royalty Pharma loan

FDA Late Cycle Meeting held; discussed REMS and label for aficamten in oHCM; PDUFA date remains Dec 26, 2025.
September 8, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Cytokinetics presents positive aficamten data at ESC 2025; PDUFA Dec 26, 2025

MAPLE-HCM: aficamten improved cardiac structure/function vs metoprolol (p<0.001 for diastolic function, SAM reduction); published in JACC.
September 3, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Cytokinetics presents new aficamten data at ESC 2025; shows improvement vs metoprolol

MAPLE-HCM: aficamten superior to metoprolol on diastolic function, SAM, and LVOT obstruction (p<0.001); reduced max wall thickness (-1.01mm, p=0.015).
September 2, 2025, 7:59 PM ET other material materiality 0.85 positive item 8.01 item 9.01

Aficamten superior to metoprolol in MAPLE-HCM Phase 3 trial; primary endpoint met (p<0.0001)

Least-squares mean pVO2 difference: +2.3 mL/kg/min (95% CI 1.5 to 3.1; p<0.0001) favoring aficamten.
August 7, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Cytokinetics Q2 net loss narrows to $134.4M; aficamten PDUFA set Dec 26, 2025

Net loss of $134.4M ($1.12/sh) vs $143.3M ($1.31/sh) in Q2 2024; revenue $66.8M from Bayer deal.
May 6, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Cytokinetics Q1 net loss $161.4M; aficamten PDUFA extended to Dec 26, 2025

Net loss $161.4M ($1.36/share) vs $135.6M ($1.33/share) in Q1 2024; revenue $1.6M.
March 10, 2025, 7:59 PM ET regulatory materiality 0.85 positive item 7.01

Cytokinetics: FDA won't hold adcom for aficamten NDA; Late Cycle meeting set for June 2025

Cytokinetics completed midcycle review with FDA for aficamten NDA treating obstructive hypertrophic cardiomyopathy.
February 27, 2025, 6:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

Cytokinetics Q4 net loss $150M, cash $1.2B; aficamten PDUFA date Sept 26, 2025

Net loss Q4 2024 was $150.0M ($1.26/sh) vs $136.9M ($1.38/sh) in Q4 2023; FY net loss $589.5M.
November 19, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01

Cytokinetics licenses aficamten Japan rights to Bayer for €50M upfront, up to €580M milestones

Upfront payment of €50 million from Bayer; additional clinical/commercial launch milestones up to €90 million.
August 8, 2024, 7:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

Cytokinetics Q2 net loss widens to $1.31/share; cash rises to $1.4B on $563M offering and $250M Royalty Pharma deal

Net loss of $143.3M ($1.31/share) vs $128.6M ($1.34/share) in Q2 2023; revenue down to $0.2M from $0.9M.
June 7, 2024, 7:59 PM ET other material materiality 0.60 neutral item 8.01

Cytokinetics raises ~$75M from underwriters' full exercise of overallotment option

Underwriters purchased 1,470,588 additional shares at $51.00 per share on June 7, 2024.
May 28, 2024, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Cytokinetics closes $500M public equity offering; concurrent $50M private placement

Closed public offering of 9,803,922 shares at $51.00; gross proceeds ~$500M.
May 22, 2024, 7:59 PM ET other material materiality 0.80 neutral item 1.01 item 2.01 item 2.03

Cytokinetics secures $200M immediate funding from Royalty Pharma; restructures aficamten royalty

Received $50M upfront from Tranche 6 term loan and $100M from 2024 DFA; plus $50M from CK-586 RPA; total $200M immediate cash.
May 13, 2024, 7:59 PM ET other material materiality 0.85 positive item 8.01 item 9.01

Aficamten Phase 3 SEQUOIA-HCM meets primary endpoint: pVO2 improved 1.8 vs 0.0 mL/kg/min (p=0.000002)

All 10 prespecified secondary endpoints met, including KCCQ-CSS (+7 points, p<0.0001) and NYHA class improvement (34%, p<0.0001).
May 8, 2024, 7:59 PM ET other material materiality 0.75 neutral item 8.01

Cytokinetics opens enrollment in CEDAR-HCM trial of aficamten in pediatric obstructive HCM

Initial cohort ~40 adolescents (12-17) with LVEF ≥60%, Valsalva LVOT-G ≥50 mmHg, NYHA ≥II.
May 8, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Cytokinetics Q1 2024 net loss $135.6M ($1.33 loss per share); cash $634M; aficamten NDA on track for Q3 2024

Net loss of $135.6M ($1.33 per share) vs $131.3M loss ($1.38 per share) in Q1 2023.
April 26, 2024, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 ◈ executive_change

Cytokinetics appoints Sung H. Lee as EVP, CFO effective May 8, 2024

Annual base salary of $550,000; target bonus 45% of base under corporate bonus plan.
April 5, 2024, 7:59 PM ET other material materiality 0.85 positive item 8.01

Cytokinetics reports positive 48-week FOREST-HCM data on aficamten at ACC

46 patients completed 48 weeks; 75% on 15mg or 20mg dose of aficamten.
February 27, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Cytokinetics reports Q4 2023 net loss of $1.38/share; positive SEQUOIA-HCM results, NDA planned for Q3 2024

Net loss Q4 2023: $136.9M ($1.38/share); full year net loss $526.2M ($5.45/share).
February 2, 2024, 6:59 PM ET leadership materiality 0.70 neutral item 5.02 ◈ executive_change

CFO Ching W. Jaw resigns effective Feb 23, 2024 for personal health reasons

SVP & CFO Ching W. Jaw resigns effective Feb 23, 2024, to attend to personal health condition.
December 27, 2023, 6:59 PM ET other material materiality 0.90 positive item 8.01

Cytokinetics announces positive Phase 3 SEQUOIA-HCM results for aficamten in obstructive HCM

Aficamten improved exercise capacity (pVO2) vs placebo: LS mean diff 1.74 mL/kg/min (p=0.000002).
November 2, 2023, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

Cytokinetics Q3 net loss $129.4M ($1.35/sh); SEQUOIA-HCM topline late Dec.

Net loss for Q3 2023 was $129.4M ($1.35/diluted share) vs $142.3M ($1.52) in Q3 2022.
August 3, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

Cytokinetics Q2 net loss widens to $128.6M; cuts 2023 spend by 15%, completes SEQUOIA-HCM enrollment

Net loss of $128.6M ($1.34 loss per share) vs $19.8M ($0.23 loss) in Q2 2022.
May 23, 2023, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Cytokinetics reports positive Phase 2 data for aficamten in nHCM; Phase 3 to start 2H 2023

At 10 weeks, aficamten improved KCCQ-CSS by 10.6 points (p<0.0001); 58% of patients had clinical symptom reduction.

Executive changes

Appointed

Robert E. Landry

Director

CYTK · CYTOKINETICS INC

Effective: 2025-02-10
Filed: February 11, 2025, 6:59 PM ET

On February 10, 2025, (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Cytokinetics, Incorporated (the “ Company ”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert E. Landry to fill a vacant Board seat and to serve as a Class II member of the Board with an initial term expiring at the Company’s 2027 annual meeting of stockholders.

Departed

Santo J. Costa

Director

CYTK · CYTOKINETICS INC

Effective: 2024-11-01
Filed: November 7, 2024, 6:59 PM ET

On November 1, 2024, Santo J. Costa notified Cytokinetics, Incorporated (the "Company") of his resignation from the Board of Directors of the Company (the "Board of Directors"), with immediate effect.

Appointed

Brett Pletcher

Executive Vice President, Chief Legal Officer

CYTK · CYTOKINETICS INC

Effective: 2024-08-19
Filed: August 15, 2024, 7:59 PM ET

On August 13, 2024, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Brett Pletcher, pursuant to which Mr. Pletcher has agreed to serve as the Company’s Executive Vice President, Chief Legal Officer, effective as of August 19, 2024 (the “Start Date”).

Departed

Sandford D. Smith

Director

CYTK · CYTOKINETICS INC

Effective: 2024-05-15
Filed: May 17, 2024, 7:59 PM ET

On May 15, 2024, Sandford D. Smith notified Cytokinetics, Incorporated (the “Company”) of his resignation from the Board of Directors of the Company (the “Board of Directors”), with such resignation effective immediately before the 2024 annual meeting of stockholders of the Company held on May 15, 2024 (the “Annual Meeting”).

Appointed

Sung H. Lee

Executive Vice President, Chief Financial Officer

CYTK · CYTOKINETICS INC

Effective: 2024-05-08
Filed: April 26, 2024, 7:59 PM ET

On April 23, 2024, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Sung H. Lee, pursuant to which Mr. Lee has agreed to serve as the Company’s Executive Vice President (“EVP”), Chief Financial Officer, effective as of May 8, 2024 (the “Start Date”).

Departed

Ching W. Jaw

Senior Vice President & Chief Financial Officer

CYTK · CYTOKINETICS INC

Effective: 2024-02-23
Filed: February 2, 2024, 6:59 PM ET

On January 29, 2024, Ching W. Jaw, Senior Vice President & Chief Financial Officer, informed Cytokinetics, Incorporated (the "Company") that he would be resigning his office and employment with the Company effective February 23, 2024.

Departed

Mark A. Schlossberg

Senior Vice President, Legal, General Counsel and Secretary

CYTK · CYTOKINETICS INC

Effective: 2022-05-13
Filed: April 15, 2022, 7:59 PM ET

On April 12, 2022, Mark A. Schlossberg, Senior Vice President, Legal, General Counsel and Secretary of Cytokinetics, Incorporated, informed Cytokinetics that he would be retiring from Cytokinetics effective May 13, 2022.

Departed

L. Patrick Gage

Director

CYTK · CYTOKINETICS INC

Effective: 2022-04-08
Filed: April 8, 2022, 7:59 PM ET

Also on the Effective Date, L. Patrick Gage, Ph.D. resigned as a director of Cytokinetics.

Appointed

Robert A. Harrington

Director

CYTK · CYTOKINETICS INC

Effective: 2022-04-08
Filed: April 8, 2022, 7:59 PM ET

On April 8, 2022, (the “Effective Date”), the Board of Directors (the “Board”) of Cytokinetics, Incorporated (the “Company”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert A. Harrington, M.D. to fill a vacant Board seat and to serve as a member of the Board with an initial term expiring at the Company’s 2024 annual meeting of stockholders.

Role change

John T. Henderson

Chairman of the Board

CYTK · CYTOKINETICS INC

Effective: 2022-04-08
Filed: April 8, 2022, 7:59 PM ET

As a result of Dr. Gage’s resignation, John T. Henderson, M.D. was appointed as Chairman of the Board.

Departed

Robert M. Califf

Director

CYTK · CYTOKINETICS INC

Effective: 2022-02-16
Filed: February 16, 2022, 6:59 PM ET

On February 16, 2022, Robert M. Califf, a member of the Board of Directors of Cytokinetics, Incorporated, resigned as a director of Cytokinetics effective immediately.

Earnings & guidance

2026-Q1 EPS reported -$1.67 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.72 · Most common event other_material

17 positive 0 negative 33 neutral

source · CYTK on sec.gov